LFMD - LifeMD: Pairing GLP-1 Agonists With Virtual Healthcare
2024-06-11 14:59:23 ET
Summary
- Identifying investment opportunities in the healthcare sector involves research on trends and next-gen tech.
- LifeMD offers telehealth services and weight management programs, positioned for growth in the underserved obesity market.
- Risks include regulatory changes, competition, cash position, and the potential need for additional funding.
- I present my plan for establishing a position in the near-term.
Finding investment opportunities in the healthcare sector is not that difficult. Some basic research on developing trends and an understanding of the next-gen tech can point you in the right direction. Indeed, once you have identified the opportunities and trends, you have to choose the best ticker that is involved or associated with the current hype. A few years ago, anything related to the COVID-19 pandemic was a hot ticker, with some names delivering impressive results and investors benefitting from their speculation. One of the hot trends during the pandemic was telehealth, as in-person care became restricted due to public health policies. Although telehealth doesn’t have the hype it had during the pandemic, the convenience factor has made it an attractive option going forward. The recent healthcare hype train is weight loss/obesity meds, which began to catch on following the pandemic as the FDA approved the label expansion of GLP-1 agonists to help take on one of the worst global public health crises. I have been a fan of both of these healthcare opportunities and have several tickers in my portfolios in these arenas. However, I don’t have many that offer a hybrid exposure like LifeMD ( LFMD ), a virtual healthcare company with pioneer technology, and a weight management program utilizing GLP-1 agonist prescriptions. I believe these two growing trends will help fuel LifeMD’s growth and will quickly move the company to break even....
LifeMD: Pairing GLP-1 Agonists With Virtual Healthcare